MedTrace Logo

The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome

NCT04422327 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-06-09

No results posted yet for this study

Summary

This study aimed to assess the impact of consumption of COMBO, a combination product of two Bifidobacterium longum strains, on stress, mood and bowel symptoms in adults with Irritable Bowel Syndrome (IBS).

Conditions

  • IBS - Irritable Bowel Syndrome
  • Depression, Anxiety

Interventions

DIETARY_SUPPLEMENT

Probiotic capsule

Each probiotic capsule contains 5 x 10\^8 CFU B. longum 35624® and 5 x 10\^8 CFU B. longum 1714™ with corn starch and magnesium stearate. The probiotic capsule will be supplied by PrecisionBiotics Ltd.

Sponsors & Collaborators

  • Atlantia Food Clinical Trials

    collaborator INDUSTRY

  • PrecisionBiotics Group Ltd.

    lead INDUSTRY

Principal Investigators

  • Eileen Murphy, PhD · PrecisionBiotics Group Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-20
Primary Completion
2018-02-12
Completion
2018-02-12

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04422327 on ClinicalTrials.gov